Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says [Yahoo! Finance]
Sionna Therapeutics (NASDAQ:SION) had its "underperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $24.00 price target on the stock.
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
Sionna Therapeutics (NASDAQ:SION) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Sionna Therapeutics (NASDAQ:SION) was upgraded by analysts at BTIG Research to a "strong-buy" rating.